BioSpace News Archive

Business

Alexandra Clyde appointed to Sequana Medical Board of Directors

Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company.

August 25, 2022
·
6 min read
KU Leuven spin-off AstriVax raises € 30 million seed capital to build vaccine platform

Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs.

August 25, 2022
·
9 min read
BioForest

Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany

Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.

August 25, 2022
·
4 min read
Business

111, Inc. Announces Second Quarter 2022 Unaudited Financial Results

111, Inc. today announced its unaudited financial results for the second quarter ended June 30, 2022.

August 25, 2022
·
21 min read
Business

AlzeCure Publishes its Interim Report for January – June 2022

AlzeCure Pharma AB announced that its interim report for the period January - June 2022 is now available on the company’s website.

August 25, 2022
·
6 min read
Business

Bionomics reports Full Year Financial Results - Aug 25, 2022

Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need.

August 25, 2022
·
4 min read
Genetown

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million.

August 25, 2022
·
3 min read
Drug Development

Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate

Pfizer Inc. announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older.

August 25, 2022
·
9 min read
Business

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

Aclaris Therapeutics, Inc. today announced a non-exclusive patent license agreement with Eli Lilly and Company (Lilly).

August 25, 2022
·
2 min read
Drug Development

Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022

Elevar Therapeutics, Inc. today announced that initial data from the Phase 3 study of its drug candidate rivoceranib was accepted for a late-breaking proffered paper presentation at the annual Congress of the European Society for Medical Oncology (ESMO) on September 10, 2022 in Paris.

August 25, 2022
·
3 min read